Type 2 diabetes, which affects >0.5 billion people worldwide, results from the inability of beta cells in the pancreatic islets to provide the body with enough insulin to maintain blood glucose levels within the range for a healthy life.
A collaborative study led by Prof. Michele Solimena at the Technische Universität in Dresden as well as the Helmholtz Zentrum München, Dr. Anke M Schulte at Sanofi in Frankfurt, Dr. Mark Ibberson at the Swiss Institute of Bioinformatics (Lausanne) and Prof. Piero Marchetti at University of Pisa as part of the EU-Innovative Medicine Initiative (IMI) research consortium IMIDIA has identified a novel cluster of dysregulated genes in the pancreatic islets of patients with type 2 diabetes. These findings are now published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).
The goal of the IMIDIA consortium, which involved 14 European academic institutions, large pharma companies and biotech firms from 02.2010 until 09.2016, was to identify novel paths for the regeneration, maintenance and protection of insulin-producing pancreatic beta cells as a mean to expedite the discovery of more effective strategies to prevent and treat diabetes.
A main task of the IMIDIA consortium was to define which genes are abnormally expressed in islet beta cells of diabetic subjects compared to islet beta cells of non-diabetic subjects. The altered expression of these genes could account for beta cell failure in diabetes. For the first time, the investigators based their comparative gene expression analysis not only on islets collected from non-diabetic and diabetic organ donors, for which the availability of clinical information is limited, but also on islets from patients undergoing pancreatic surgery.
For the latter subjects in depth medical information was available and the diabetic status could be accurately assessed immediately prior to surgery. This approach enabled therefore the assembly of the largest collection of islets from non-diabetic and diabetic subjects, but also access to islets from prediabetic individuals. The investigators identified in this way nineteen genes the expression of which was altered in islets of both diabetic organ donors as well as diabetic surgical patients, as compared with non-diabetic islets from these cohorts.
Notably, nine of these nineteen genes had never been shown previously to be dysregulated in diabetic islets. On the other hand, the study could not find evidence for any of these genes to be dysregulated in islets of prediabetic subjects, hence suggesting that their altered expression is a consequence rather than the cause of beta cell failure in diabetes. Hence, future studies shall be devoted to discover which genes are dysregulated prior to the demise of the beta cells.
For this purpose, more islets must be collected from prediabetic subjects and this is precisely one of the main tasks pursued by the recently launched EU-IMI consortium RHAPSODY, which includes all four teams leading the present IMIDIA study as partners.
“We believe that our data provides novel molecular insights into what is going wrong in diabetic beta cells and sets new standards for how studies in this field shall be carried out in the future. Ultimately, we are confident that our approach will provide a new view for how exposure of beta cells to nutrient overload wears their function overtime, hence impairing their ability to satisfy the excessive demand of insulin to maintain metabolic homeostasis” says Prof. Michele Solimena, one of the four leading investigators of this study
IMIDIA (“Innovative Medicines Initiative for Diabetes”, www.imidia.org) is a public private consortium funded by the Innovative Medicines Initiative (IMI) and is led by Sanofi, Servier and the University of Lausanne. Leading European experts from 14 academic institutions, eight pharmaceutical research organizations and one biotech company in the area of pancreatic beta cells officially joined their forces within the IMIDIA project to fight diabetes. IMIDIA is working on the generation of novel, patient centric tools, biomarkers, and fundamental knowledge on beta cell organization to accelerate the path to improved diabetes management. It is a unique collaboration of leading research groups in Europe focusing on the necessary innovation tightly coupled with the applications and evaluation of these results to develop new diagnostics, prognostics and therapeutics. Approximately 100 researchers operating in six different scientific work packages focus on novel approaches e.g. imaging biomarkers, systems biology and pathway analysis with the goal of developing patient relevant disease models in vitro and in vivo as well as biomarkers to monitor disease progression and treatment.
IMIDIA participants were AstraZeneca, Boehringer Ingelheim, the French Atomic Energy Commission (CEA), Hannover Medical School (MHH), Imperial College London, Lilly, the National Centre for Scientific Research (CNRS), the National Institute of Health and Medical Research (INSERM), Novartis, Novo Nordisk, Roche, Sanofi, Sarl Endocells, Servier, SIB Swiss Institute of Bioinformatics, Vrije University of Brussels, Technische Universität Dresden, University of Geneva, University of Lausanne, University Paris Diderot and University of Pisa. Additional financial support for this study was provided by the German Center for Diabetes Research (DZD e.V.), which is supported by the German Ministry for Education and Research; the Italian Ministry of Education and Research, and by the Wellcome Trust, the Medical Research Council and the Royal Society in the UK.
Title: Systems biology of the IMIDIA biobank from organ donors and pancreatectomised patients defines a novel transcriptomic signature of islets from individuals with type 2 diabetes.
Solimena et al.2017, Diabetologia, DOI: https://doi.org/10.1007/s00125-017-4500-3
Hidden link for journalists: http://www.diabetologia-journal.org/files/solimena.pdf
Link article on SpringerLink: http://link.springer.com/article/10.1007/s00125-017-4500-3
Prof. Dr. Michele Solimena
Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital Carl Gustav Carus and Faculty of Medicine TU Dresden
Fetscherstrasse 74 01307 Dresden , Germany
Dr. Anke Schulte
Sanofi-Aventis Deutschland GmbH Diabetes Research
Industriepark Höchst, Building H821, 65926 Frankfurt am Main, Germany
Dr. Mark Ibberson
Vital-IT Group, SIB Swiss Institute of Bioinformatics Quartier Sorge, bâtiment Génopode,
1015 Lausanne, Switzerland
Prof. Dr. Piero Marchetti
Department of Clinical and Experimental Medicine Cisanello University Hospital
University of Pisa Via Paradisa 2 56126 Pisa, Italy
Dr. Frank Möller
Scientific Coordinator Paul Langerhans Institute Dresden
Tel.: +49 (0) 351 796 5634
Kim-Astrid Magister | Technische Universität Dresden
Don't Give the Slightest Chance to Toxic Elements in Medicinal Products
23.03.2018 | Physikalisch-Technische Bundesanstalt (PTB)
North and South Cooperation to Combat Tuberculosis
22.03.2018 | Universität Zürich
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Materials Sciences
23.03.2018 | Agricultural and Forestry Science
23.03.2018 | Physics and Astronomy